OAC
HUMA icon

OMERS Administration Corp’s Humacyte HUMA Stock Holding History

OMERS Administration Corp’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-19,600
Closed -$94.1K – 978
2024
Q2 		$94.1K Buy
+19,600
New +$102K ﹤0.01% 946

Other funds holding HUMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

OMERS Administration Corp's HUMA Position: Q3 2024 in Review

OMERS Administration Corp sold out of Humacyte (HUMA) in Q3 2024, closing a stake of 19,600 shares — an estimated $94.1K sold.

OMERS Administration Corp first reported a position in HUMA in Q2 2024 and held it in 1 quarter. The position peaked at $94.1K in Q2 2024. 143 funds tracked by Wall St. Rank hold HUMA as of Q3 2024.

  • OMERS Administration Corp reported no remaining Humacyte position as of Q3 2024 after selling out during the quarter.
  • OMERS Administration Corp sold 19,600 Humacyte shares in Q3 2024, an estimated $94.1K.
  • OMERS Administration Corp first reported a position in Humacyte in Q2 2024 and held it in 1 quarter.
  • OMERS Administration Corp's Humacyte position peaked at $94.1K in Q2 2024.
  • 143 funds tracked by Wall St. Rank held Humacyte as of Q3 2024.

Based on OMERS Administration Corp's 13F filing for Q3 2024, filed 13 Nov 2024.